E
TARA icon

Ergoteles’s Protara Therapeutics TARA Stock Holding History

Ergoteles’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-17,700
Closed -$172K – 1650
2021
Q2 		$172K Buy
+17,700
New +$201K ﹤0.01% 1322

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ergoteles's TARA Position: Q3 2021 in Review

Ergoteles sold out of Protara Therapeutics (TARA) in Q3 2021, closing a stake of 17,700 shares — an estimated $172K sold.

Ergoteles first reported a position in TARA in Q2 2021 and held it in 1 quarter. The position peaked at $172K in Q2 2021. 36 funds tracked by Wall St. Rank hold TARA as of Q3 2021.

  • Ergoteles reported no remaining Protara Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Ergoteles sold 17,700 Protara Therapeutics shares in Q3 2021, an estimated $172K.
  • Ergoteles first reported a position in Protara Therapeutics in Q2 2021 and held it in 1 quarter.
  • Ergoteles's Protara Therapeutics position peaked at $172K in Q2 2021.
  • 36 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.